A comprehensive new analysis published in The Lancet casts significant doubt on the widespread belief that medicinal cannabis effectively treats common mental health conditions like anxiety, depression, and post-traumatic stress disorder (PTSD). The study, the largest of its kind to date, reviewed data from 54 randomized controlled trials spanning 45 years and found little to no evidence supporting the use of cannabinoids for these purposes. This finding arrives as cannabis use for medical reasons continues to rise, with approximately 27% of adults aged 16-65 in the United States and Canada reporting medical cannabis use, and roughly half citing mental health symptoms as the reason, according to researchers.
The research team, led by Dr. Jack Wilson of the University of Sydney’s Matilda Centre, suggests that the routine prescription of medicinal cannabis for anxiety, depression, and PTSD may not only be ineffective but potentially harmful. “Though our paper didn’t specifically glance at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments,” Dr. Wilson explained. The study underscores a growing concern among medical professionals about the increasing availability and use of cannabis products without sufficient scientific backing.
Limited Benefits Found in Specific Cases
While the study largely debunked the use of medicinal cannabis for core mental health disorders, researchers did identify some limited indications of potential benefit in specific areas. These included cannabis use disorder – often referred to as cannabis dependency – as well as autism, insomnia, and tic disorders like Tourette’s syndrome. However, Dr. Wilson cautioned that the evidence supporting these uses remains weak. “But the overall quality of evidence for these other conditions, such as autism and insomnia, was low,” he stated. “In the absence of robust medical or counseling support, the use of medicinal cannabis in these cases are rarely justified.”
The researchers similarly noted existing evidence supporting the use of medicinal cannabis for certain physical health conditions, including reducing seizures associated with some forms of epilepsy, managing spasticity in individuals with multiple sclerosis, and alleviating certain types of pain. However, these benefits do not extend to the realm of mental health disorders, according to the study’s findings. The National Institute of Neurological Disorders and Stroke provides further information on epilepsy and its treatment options on their website.
Substance Use Disorders: A Mixed Picture
The analysis also explored the impact of medicinal cannabis on various substance use disorders, revealing a complex and sometimes contradictory picture. Interestingly, cannabis-based treatments showed some promise in assisting individuals struggling with cannabis dependence. The study suggested that, when combined with psychological therapy, an oral formulation of cannabis could facilitate reduce cannabis smoking, mirroring the approach used with methadone in opioid-use disorder treatment.
However, a concerning finding emerged regarding cocaine-use disorder. The study revealed that medicinal cannabis use actually increased cravings among individuals with this addiction. “So it should not be considered for this purpose and may, in fact, worsen cocaine dependence,” Dr. Wilson emphasized. This highlights the importance of carefully considering the potential interactions between cannabis and other substances.
Calls for Increased Regulation and Evidence-Based Prescribing
The rapid expansion of the medicinal cannabis market has prompted growing calls for stricter regulation and a greater emphasis on evidence-based prescribing practices. Organizations like the American Medical Association have expressed concerns about the limited regulation and the ongoing uncertainty surrounding the effectiveness and safety of these products. The AMA has published several policy statements on cannabis, advocating for further research and responsible regulation on their website.
“Our study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which may support clinicians to make evidence-based decisions, helping to ensure patients receive effective treatments while minimising harm from ineffective or unsafe cannabis products,” Dr. Wilson said. The researchers hope their findings will encourage a more cautious and informed approach to the prescription of medicinal cannabis, particularly for mental health conditions.
Understanding the Study Methodology
The findings are based on a rigorous systematic review and meta-analysis of 54 randomized controlled trials (RCTs) conducted globally over a 45-year period (1980-2025). This comprehensive approach aimed to provide a robust and unbiased assessment of the available evidence. The research was funded by the National Health and Medical Research Council (NHMRC) of Australia. The authors disclosed potential conflicts of interest, including consultation fees received by Wayne Hall and Myfanwy Graham from the World Health Organization, and funding received by Myfanwy Graham from the Therapeutic Goods Administration for independent evidence reviews on medicinal cannabis.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. We see essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Looking ahead, researchers emphasize the need for continued, high-quality research to better understand the potential benefits and risks of medicinal cannabis. The next step will be to investigate the long-term effects of cannabis use on mental health and to identify specific patient populations who may benefit from targeted interventions. The Australian government is expected to release updated guidelines on medicinal cannabis prescribing in early 2026, based on ongoing research and expert recommendations.
Have thoughts on this story? Share your comments below and join the conversation.
